Subsequent Events

12 Months Ended

Dec. 31, 2020

Subsequent Events [Abstract]

Subsequent Events

Note 22. Subsequent Events

(A) License Agreement with Mitsubishi Tanabe

On January 21, 2021, the Company entered into an exclusive license agreement with Mitsubishi Tanabe Pharma America, Inc. for the commercialization in the United States of Exservan® (riluzole), an oral film formulation of riluzole for treatment of amyotrophic lateral sclerosis (ALS).

(B) Continued Utilization of the At-The-Market Facility

The Company continued utilization of its At-The-Market facility from January 1 through March 5, 2021 and sold 1,644,715 shares which generated net proceeds of approximately $9,749.

(C) Stockholder Class Action

On March 1, 2021, a securities class action lawsuit was filed in the United States District Court of the District of New Jersey alleging that the Company and certain of its officers engaged in violations of the federal securities laws relating to public statements made by the Company relating to the approval of Libervant. We are not able to determine or predict the ultimate outcome of this proceeding or provide a reasonable estimate or range of estimates of the possible outcome or loss, if any, in this matter.